Class of diabetes drug linked to increased risk of irritable bowel disease

Class of diabetes drug linked to increased risk of irritable bowel disease

March 29 2018 A study has shown that dipeptidylpeptidase-4 inhibitors may increase the risk of...

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

March 29 2018 Mefloquine is safe to use for malaria prevention during pregnancy, a Cochrane...

Anti-epilepsy drugs exposure in womb associated with poor school performance years later

Anti-epilepsy drugs exposure in womb associated with poor school performance years later

March 27 2018 Exposure to anti-epilepsy drugs in the womb has been linked to significantly poorer...

COPD flare-ups may only need 5 days of systemic steroids

COPD flare-ups may only need 5 days of systemic steroids

March 26 2018 A new study has suggested that shorter doses of systemic corticosteroids may be as...

Numbers of people with heart condition living with multiple other diseases increases

Numbers of people with heart condition living with multiple other diseases increases

March 12 2018 Almost a quarter of people (24.3%) with heart disease are also living with five or...

  • Class of diabetes drug linked to increased risk of irritable bowel disease

    Class of diabetes drug linked to increased risk of irritable bowel disease

    Thursday, 29 March 2018 11:49
  • Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Cochrane review indicates mefloquine is safe in pregnancy, but adverse effects are a barrier to use

    Thursday, 29 March 2018 11:46
  • Anti-epilepsy drugs exposure in womb associated with poor school performance years later

    Anti-epilepsy drugs exposure in womb associated with poor school performance years later

    Tuesday, 27 March 2018 10:08
  • COPD flare-ups may only need 5 days of systemic steroids

    COPD flare-ups may only need 5 days of systemic steroids

    Monday, 26 March 2018 12:53
  • Numbers of people with heart condition living with multiple other diseases increases

    Numbers of people with heart condition living with multiple other diseases increases

    Monday, 12 March 2018 16:45

a man taking medication imageNovember 10 2017

Doxycycline should not be used for post-exposure prophylaxis (PEP) for sexually transmitted infections, says new guidance. Any potential benefits are “outweighed by the considerable potential for antibiotic resistance to develop in STIs and other bacteria.”

Members of the public who may be searching online for doxycycline PEP should be advised that antibiotics should only be prescribed by a health professional and use diagnostic testing.

A position statement issued jointly by Public Health England and the British Association for Sexual Health and HIV (BASHH) says more research is needed to assess the wider impact of prophylactic doxycycline on antimicrobial resistance (AMR) at an individual and population level. Instead, the organisations state: “We recommend the use of antibiotics as prescribed by a healthcare professional and as indicated by the results of a suitable diagnostic test.”

The statement refers to a study published earlier this year which had found that doxycycline PEP had halved the rates of bacterial STIs in men who have sex with men (MSM), in an extension of the French IPERGAY trial. “Many of the online companies selling HIV Pre-exposure Prophylaxis (PrEP) in the form of tenofovir disoproxil fumarate 300mg / emtricitabine 200mg are now making doxycycline available to UK buyers,” says the statement.

“A high rate of STIs without doxycycline PEP was shown (69.7 events per 100-person years of follow-up) and the antibiotic strategy showed an overall reduction in STI incidence of 47%. There was a significant decrease in chlamydia and syphilis incidence with reductions of 70 and 73% respectively in intent to treat analyses but no clear benefit was shown for gonorrhoea, likely due to the high rate of doxycycline resistance already developed.”

The PHE /BASHH statement adds: “For those at risk, following condomless sex, we recommend STI testing at appropriate window periods and the treatment of any infections identified should be prescribed by a healthcare professional and be in line with published national guidance. We recommend that the use of doxycycline PEP should be restricted to the research setting at present.”

Links:
PHE announcement       
BASHH announcement  
PHE/BASHH ‘Position Statement on Doxycycline as PostExposure Prophylaxis for Sexually Transmitted Infections’ November 2017                  

Clinical News

April 20 2018 Wide variation in gluten-free food (GFF) prescribing does not appear to be driven by obvious medical factors, a study has suggested. 
April 20 2018 Wide variation in gluten-free food (GFF) prescribing does not appear to be driven by obvious medical factors, a study has suggested.  GFF prescribing is less likely to occur in areas...